Fibrous Dysplasia Market
Number of pages: 100 | Report Format: PDF | Published date: April 24, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
7.2% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Treatment, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global fibrous dysplasia market is expected to grow at a revenue CAGR of 7.2% from 2023 to 2031.
Fibrous Dysplasia Market Fundamentals
Fibrous dysplasia is a rare genetic disorder that affects the bones, causing abnormal growth and development of fibrous tissue instead of normal bone. This condition can occur in any body part and affect one or multiple bones. The cause of fibrous dysplasia is a genetic mutation that affects bone-forming cells known as osteoblasts. The mutation causes these cells to produce abnormal bone tissue, which is weak and prone to fractures. Two main fibrous dysplasia types are monostotic (affecting only one bone) and polyostotic (affecting multiple bones). Fibrous dysplasia symptoms can vary depending on the location and severity of the condition. Some people may have no symptoms, while others may experience bone pain, deformities, fractures, and restricted movement. Fibrous dysplasia treatment options include medications to reduce pain and prevent bone loss, surgery to correct deformities and prevent fractures, and physical therapy to improve mobility and function.
Fibrous Dysplasia Market Dynamics
As more people are diagnosed with fibrous dysplasia, the demand for effective treatments will likely grow. With the increasing understanding of genetics and personalized medicine, there has been a growing interest in developing targeted therapies for rare diseases like fibrous dysplasia. These treatments aim to address the underlying genetic causes of the condition and have the potential to be more effective and have fewer side effects than traditional treatments. With the high cost and long development timelines associated with developing new drugs, there has been a growing interest in drug repurposing. This involves identifying existing drugs that may be effective in treating rare diseases like fibrous dysplasia and repurposing them for this indication.
Regulatory agencies like the FDA and EMA have implemented various incentives to encourage the development of treatments for fibrous dysplasia. These incentives include expedited review processes, tax credits, and market exclusivity, which can help stimulate investment in developing new treatments. Moreover, patient advocacy organizations are significantly raising awareness about rare diseases and advocating for increased investment in research and development. As more people with fibrous dysplasia engage in patient advocacy, this could help drive further investment and innovation in this area.
However, developing new treatments for diseases like fibrous dysplasia can be expensive, as there is often a lack of existing research and clinical data, restricting the fibrous dysplasia market revenue growth. As fibrous dysplasia is a rare disease, the commercial potential of new treatments may be limited. This can make it difficult for pharmaceutical companies to justify the investment required to develop and market new treatments, thus hindering the fibrous dysplasia market revenue growth.
Fibrous Dysplasia Market Ecosystem
The global fibrous dysplasia market is analyzed from three perspectives: type, treatment, and region.
Fibrous Dysplasia Market by Type
[76966]
Based on the type, the global fibrous dysplasia market is segmented into monostotic fibrous dysplasia and polyostotic fibrous dysplasia.
The monostotic fibrous dysplasia segment dominated the fibrous dysplasia market with the largest revenue share in 2022. Monostotic fibrous dysplasia is the more common type of fibrous dysplasia. According to the National Center for Biotechnology, it accounts for around 70% to 80% of all cases. Patients with monostotic fibrous dysplasia generally have a better prognosis than those with polyostotic fibrous dysplasia. Monostotic fibrous dysplasia usually has a slow progression and is less likely to cause complications, whereas polyostotic fibrous dysplasia can cause significant morbidity and mortality. Several treatment options for monostotic fibrous dysplasia are currently available, including surgery, bisphosphonates, and calcitonin. This provides a greater range of options for patients and physicians and may make it easier for pharmaceutical companies to develop new treatments for this condition. Monostotic fibrous dysplasia has been the subject of more research than polyostotic fibrous dysplasia, as it is more common and easier to study. This may have led to a greater understanding of the condition and more effective treatments being developed.
The polyostotic fibrous dysplasia segment accounted for a considerable revenue share of the fibrous dysplasia market. Polyostotic fibrous dysplasia accounts for 20-25% of all cases of fibrous dysplasia. It is often more severe than monostotic fibrous dysplasia, with patients experiencing multiple bone lesions, fractures, deformities, and other complications. This can lead to a greater need for treatment and management and a larger market for pharmaceutical companies. Patients with polyostotic fibrous dysplasia are at a higher risk of developing complications, such as hearing loss and endocrine dysfunction. This can lead to a higher demand for treatments to prevent or manage these complications.
Additionally, polyostotic fibrous dysplasia is a complex condition with multiple bone lesions and endocrine abnormalities, and there is a significant need for innovative and effective treatments that can address these complex symptoms. This creates an opportunity for pharmaceutical companies to develop new treatments to improve outcomes for patients with this condition. There is less research on polyostotic fibrous dysplasia than monostotic fibrous dysplasia, but a significant amount of research is still being conducted on this condition. This may lead to developing new insights and treatments that can improve patient outcomes.
Fibrous Dysplasia Market by Treatment
Based on the treatment, the global fibrous dysplasia market is segmented into surgery and medication.
The surgery segment accounted for a significant revenue share of the fibrous dysplasia market in 2022. Surgery is often considered an effective treatment option for fibrous dysplasia, particularly in cases where the lesions are causing pain, deformity, or other complications. Surgery can remove the affected tissue and improve patients' symptoms and quality of life. Surgery is a widely available treatment option for fibrous dysplasia and is often offered by many hospitals and medical centers. This means that patients with fibrous dysplasia have easy access to surgical treatment, which can contribute to its popularity and market share. Surgery has been used to treat fibrous dysplasia for many years, and it is a well-established procedure with a proven track record. This can give patients and physicians confidence in its effectiveness and safety, contributing to its use as a treatment option. Several different surgical options are available for fibrous dysplasia, including curettage, bone grafting, and osteotomy. This provides physicians with a range of options to tailor treatment to the specific needs of each patient, which can make surgery a more flexible and effective treatment option.
The medication segment accounted for a significant fibrous dysplasia market revenue share in 2022. The medication segment is further sub-segmented into bisphosphonates and denosumab. Medication is a non-invasive treatment option for fibrous dysplasia, which can appeal to patients who prefer to avoid surgery. Medication can be taken orally or by injection, making it a convenient and accessible treatment option. Several medication options are available for fibrous dysplasia, including bisphosphonates and denosumab, which can be used alone or combined to manage symptoms and prevent bone loss. This gives physicians various options to tailor treatment to each patient's needs. Medication can be used for long-term treatment of fibrous dysplasia, which may be necessary in cases where surgery is not an option or where lesions continue to grow despite surgery. This can make medication a more attractive treatment option for patients who require ongoing management of their condition. There is ongoing research into new medication options for fibrous dysplasia, which may lead to the development of new and more effective treatments. This can contribute to the popularity of medication as a treatment option and its market revenue share.
Fibrous Dysplasia Market by Region
Based on region, the global fibrous dysplasia market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounts for a large market revenue share due to an increasing prevalence of fibrous dysplasia. The rise in the incorporation of advanced imaging techniques such as CT and MRI has made it easier to diagnose fibrous dysplasia. This has led to an increase in the number of cases diagnosed and has also allowed for earlier detection and treatment. There is ongoing research into new treatments and therapies for fibrous dysplasia. This includes the development of new drugs, as well as new surgical and non-surgical approaches. As these new treatments become available, they are expected to drive revenue growth in the fibrous dysplasia market in North America. As personalized medicine becomes more common in North America, there is increasing demand for treatments tailored to individual patients. This is particularly important for fibrous dysplasia, which can manifest differently and require different treatment approaches depending on the patient's needs. There is growing awareness of fibrous dysplasia among healthcare professionals, patients, and their families. This leads to earlier diagnosis and treatment and increasing demand for new treatments and therapies in the region.
Asia Pacific has the fastest revenue CAGR in the fibrous dysplasia market during the forecast period. In many countries in the Asia Pacific, there is growing awareness of fibrous dysplasia among healthcare professionals, patients, and their families. This has led to an increase in the number of cases diagnosed and has also allowed for earlier detection and treatment. Fibrous dysplasia is considered a rare disease, and the prevalence of rare diseases is increasing in Asia. This drives demand for treatments and therapies for rare diseases such as fibrous dysplasia. Countries in the Asia Pacific are investing in healthcare infrastructure, improving access to diagnosis and treatment for rare diseases such as fibrous dysplasia. There is ongoing research into new treatments and therapies for fibrous dysplasia, including developing new drugs and new surgical and non-surgical approaches. As these new treatments become available, they are expected to drive revenue growth in the Asia Pacific fibrous dysplasia market. Additionally, personalized medicines are becoming more common in Asia Pacific, and there is increasing demand for treatments tailored to individual patients. This is particularly important for fibrous dysplasia, which can manifest differently and require different treatment approaches depending on the patient's needs.
Fibrous Dysplasia Market Competitive Landscape
The prominent players operating in the global fibrous dysplasia market are:
Fibrous dysplasia is a rare genetic disorder that affects the bones, causing abnormal growth and development of fibrous tissue instead of normal bone. This condition can occur in any body part and affect one or multiple bones. The cause of fibrous dysplasia is a genetic mutation that affects bone-forming cells known as osteoblasts.
Asia Pacific can be considered the key growth region due to the surge in fibrous dysplasia industry trends in China, Japan, and the Indian subcontinent.
The prominent players operating in the global fibrous dysplasia market are Pfizer Inc., Amgen Inc., Novartis AG, Bayer AG, and AVEO Pharmaceuticals Inc.
The monostotic fibrous dysplasia segment dominated the global Klinefelter syndrome hormone therapy market.
The global fibrous dysplasia market is expected to register a revenue CAGR of 7.2%.
*Insights on financial performance are subject to the availability of information in the public domain